Salem Investment Counselors’s Cocrystal Pharma COCP Stock Holding History

Salem Investment Counselors’s Portfolio COCP Stock Details COCP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-1	Closed	–	–	863
2020 Q4	$0	Buy	+1	New	+$14	﹤0.01%	804

Other funds holding COCP

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Salem Investment Counselors's COCP Position: Q1 2021 in Review

Salem Investment Counselors sold out of Cocrystal Pharma (COCP) in Q1 2021, closing a stake of 1 share.

Salem Investment Counselors first reported a position in COCP in Q4 2020 and held it in 1 quarter. The position peaked at $0 in Q4 2020. 35 funds tracked by Wall St. Rank hold COCP as of Q1 2021.

Salem Investment Counselors reported no remaining Cocrystal Pharma position as of Q1 2021 after selling out during the quarter.
Salem Investment Counselors sold 1 Cocrystal Pharma share in Q1 2021.
Salem Investment Counselors first reported a position in Cocrystal Pharma in Q4 2020 and held it in 1 quarter.
Salem Investment Counselors's Cocrystal Pharma position peaked at $0 in Q4 2020.
35 funds tracked by Wall St. Rank held Cocrystal Pharma as of Q1 2021.

Based on Salem Investment Counselors's 13F filing for Q1 2021, filed 17 May 2021.